RACEPHEDRINE SULFATE

US Approved OTC

First approved in 1961

Details

Stereochemistry	RACEMIC
Molecular Formula	C10H15NO.H2O4S
Molecular Weight	263.311
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.CN[C@H](C)[C@@H](O)C1=CC=CC=C1

InChI

InChIKey=XVPDSDYVNYOVMP-GHXDPTCOSA-N

InChI=1S/C10H15NO.H2O4S/c1-8(11-2)10(12)9-6-4-3-5-7-9;1-5(2,3)4/h3-8,10-12H,1-2H3;(H2,1,2,3,4)/t8-,10-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H15NO
Molecular Weight	165.2322
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5744603 | https://www.ncbi.nlm.nih.gov/pubmed/21796845

Racephedrine in combination with theophylline, phenobarbital was used to treat bronchial asthma. However, its application was substituted more effective agent. In addition, FDA has reviewed the final monograph for over-the-counter bronchodilator drug products to add additional warnings and to revise the indications in the labeling of products containing racephedrine hydrochloride.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Asthma 244 Sources: https://www.ncbi.nlm.nih.gov/pubmed/5744603	Palliative		Approved 8583	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
79.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/	22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered:		EPHEDRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
751 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/	22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered:		EPHEDRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
6.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/	22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered:		EPHEDRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
activator 150 inhibitor 2252

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 2633	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/885#sid=26748236	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/884#sid=26748236	no

Sourcing

Vendor/Aggregator	ID	URL
Acros Organics	22787
Bide Pharmatech	BD0282
BOC Sciences	53214-57-6
BOC Sciences	670-40-6
Chemspace	CSC015963191
Compound Cloud	71290
Compound Cloud	9457
Debye Scientific	DA-05155
eMolecules	300001892
eMolecules	4688326
Enamine	BBV-79210044
Enamine	BBV-79216575
Enamine	BBV-82112918
Enamine	BBV-82114259
Hairui	HR125855
Hairui	TIJL03005
HongKong Chemhere	321-97-1
HongKong Chemhere	SCA55889
HongKong Chemhere	SCA57351
IBScreen	STOCK5S-54243
KeyOrganics	STR02792
Lab Network	LN00753918
mcule	MCULE-5892842695
mcule	MCULE-9848295327
MolPort	MolPort-000-725-693
MolPort	MolPort-001-769-085
MuseChem	M094388
MuseChem	R022094
NCI Plated 2007	165609
NCI Plated 2007	170951
NCI Plated 2007	171244
NCI Plated 2007	33634
NCI Plated 2007	8971
Pharmeks	PHAR036497
Pharmeks	PHAR363096
Princeton BioMolecular Research	OSSL_123892
Sigma Aldrich	285749\|ALDRICH
Sigma Aldrich	45280\|SIAL
Sigma Aldrich	E-011\|CERILLIAN
Sigma Aldrich	E0305000
Sigma Aldrich	E0305000\|SIAL
Tetrahedron	TS16810
Tetrahedron	TS42942
TimTec	ST51038173
Toronto Research Chemicals	E575000
Toronto Research Chemicals	E575005
Toronto Research Chemicals	E575205
Vitas-M Laboratory	BBL010298
Vitas-M Laboratory	STK367993
Vitas-M Laboratory	STL326624
ZINC	ZINC000000074840	http://zinc15.docking.org/substances/ZINC000000074840

PubMed

Title	Date	PubMed
Labeling for bronchodilators to treat asthma; cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. Final rule.	2011-07-26	21796845
[The in-vitro histamine liberation in human leukocytes sensitized by grass pollen. Pharmacological application of the study on racephedrine and theophylline (proceedings)].	1977-06	70946
[Delayed-action effect of a racephedrine, theophylline and phenobarbital combination on asthma. Study on 100 cases].	1968-07-01	5744603
A racephedrine-phenyltoloxamine-containing compound (Ephoxamine) in the treatment of bronchial asthma.	1961-07	13775237
RACEPHEDRINE hydrochloride capsules.	1949-07-01	18146174

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:39:25 GMT 2025` Edited by `admin` on `Mon Mar 31 20:39:25 GMT 2025`
Record UNII	730X185N08
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RACEPHEDRINE SULFATE

Common Name

English

DL-EPHEDRINE SULFATE

Preferred Name

English

BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (R*,S*)-, SULFATE (2:1) (SALT)

Systematic Name

English

(1RS,2SR)-2-(METHYLAMINO)-1-PHENYLPROPAN-1-OL SULFATE

Systematic Name

English

RACEPHEDRINE MONOSULFATE

Common Name

English

EPHEDRINE SULFATE, DL

Common Name

English

Code System Code Type Description

CAS

154-45-0